Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HRH2 | P25021 | 4/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3599687 | 1.00 | KMT2A (0.40) | KMT2AHRH2MAPK1SLC2A1GAA | |
| SCHEMBL3596388 | 0.94 | SIGMAR1 (0.39) | KMT2AMAPK1SIGMAR1PTGDR2CCR5 | |
| SCHEMBL3592620 | 0.94 | MAPK1 (0.37) | HRH2MAPK1ACHESIGMAR1CCR5 | |
| SCHEMBL3598755 | 0.94 | ALDH1A1 (0.38) | KMT2AHRH2MAPK1ACHESIGMAR1 | |
| SCHEMBL3590665 | 0.94 | MAPK1 (0.37) | HRH2MAPK1ACHESIGMAR1CCR5 | |
| SCHEMBL3598750 | 0.94 | ALDH1A1 (0.38) | KMT2AHRH2MAPK1ACHESIGMAR1 | |
| SCHEMBL3591379 | 0.94 | HRH2 (0.38) | KMT2AHRH2MAPK1ACHESIGMAR1 | |
| SCHEMBL3591374 | 0.94 | HRH2 (0.38) | KMT2AHRH2MAPK1ACHESIGMAR1 | |
| SCHEMBL3592739 | 0.93 | MAPK1 (0.37) | KMT2AHRH2MAPK1ACHESIGMAR1 | |
| SCHEMBL3602656 | 0.93 | MAPK1 (0.37) | KMT2AHRH2MAPK1ACHESIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| EP-1930320-A1 | NOVEL FUSED PYRROLE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | NR3C1, NR3C2, NR0B1 | KMT2A 4721/4885HRH2 1095/4885MAPK1 703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.